Raltitrexed
PD-1
First Hospital of China Medical UniversitySmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the PD-1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tuvonralimab Anhui Provincial Hospital | Phase 2 | CCC |
Ruxoprubart Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 | CCC |
Iparomlimab Anhui Provincial Hospital | Phase 2 | CCC |
LENVATINIB The First Affiliated Hospital with Nanjing Medical University | Phase 2 | CCC |
Dasatinib The Affiliated Hospital of Qingdao University | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Raltitrexed is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →